Life Sciences

  • June 17, 2025

    Dexcom Faces TM Suit Over 'Stelo' Glucose Monitor Product

    Software company StarQuest Ventures Inc., which does business as Stelo, has hit Dexcom with a trademark infringement suit alleging the use of the 'Stelo' name for Dexcom's glucose monitoring system has caused significant consumer confusion and damaged Stelo's brand.

  • June 17, 2025

    FDA Unveils Voucher Program For Fast-Paced Drug Reviews

    Pharmaceutical companies that boost domestic drug manufacturing or address other national priorities will have a chance to secure speedier review and approval of new drugs under a pilot program the U.S. Food and Drug Administration unveiled Tuesday.

  • June 17, 2025

    9th Circ. Backs Class Cert. In Suit Over Diabetes Drug Risk

    The Ninth Circuit refused to disband a class of third-party payors who claim Takeda Pharmaceutical and Eli Lilly & Co. hid their anti-diabetes drug's bladder cancer risks, finding no issue with a lower court's analysis of expert evidence showing prescriptions fell after the risks were disclosed.

  • June 17, 2025

    Judge Hints Zantac Makers Likely Stuck With Cancer Risk Suit

    Despite parallel litigation in Delaware, a Connecticut judge on Tuesday hinted that he might not be able to dismiss an estate's generic Zantac lawsuit against three brand-name drugmakers over the heartburn medication's alleged link to cancer risk, saying binding precedents allow him to toss similar cases between the same parties only if both cases were filed in Connecticut.

  • June 17, 2025

    Ozempic, Wegovy Users Want NJ To Host Vision-Loss Suits

    Twenty-one New Jersey-based plaintiffs who claim they suffered permanent vision loss after taking the blockbuster drugs Ozempic and Wegovy are seeking to consolidate their lawsuits as multicounty litigation against drugmaker Novo Nordisk, citing a growing body of scientific evidence linking the medications to a rare and irreversible eye condition.

  • June 17, 2025

    Surgery Partners Rejects $3.3B Bain Offer, Eyes Public Growth

    Surgery Partners, a short-stay surgical facility owner, said on Tuesday it has ended talks with Bain Capital regarding a nearly $3.3 billion take-private proposal, saying it sees a stronger future as a public company.

  • June 17, 2025

    Medical AI Co. Calls Rival's Suit A Ploy To Kill Competition

    A Canadian artificial intelligence company focusing on medical information has asked a Massachusetts federal judge to toss out a recent trade secrets lawsuit, saying the complaint is an attempt to thwart competition based solely on speculation.

  • June 17, 2025

    Kirkland-Led Lilly Inks $1.3B Deal For Cardio Drug Co. Verve

    Kirkland-advised Eli Lilly and Co. said Tuesday it will acquire Paul Weiss-advised Verve Therapeutics in a deal worth up to $1.3 billion, continuing its push into next-generation genetic medicines for heart disease.

  • June 16, 2025

    Doctor Will Admit Dealing Ketamine That Killed Matthew Perry

    A physician has agreed to plead guilty to helping supply the ketamine that killed "Friends" star Matthew Perry, according to a plea agreement filed in California federal court Monday.

  • June 16, 2025

    Life Spine Accuses Ex-CEO Of Stealing Money, Trade Secrets

    Spinal device maker Life Spine slapped its founder with a civil suit in Illinois state court Friday accusing him of embezzling millions of dollars from the company through fraudulent credit card charges for motorsports, a lavish Mexico vacation for his family, customized golf clubs, jewelry and a Porsche for his wife. 

  • June 16, 2025

    Catching Up With Delaware's Chancery Court

    Delaware's Court of Chancery this past week sought answers in the high-stakes battle over the constitutionality of newly enacted Delaware corporation law amendments, which will hitch a ride to the state's Supreme Court via a suit contesting a $117 million acquisition of Clearway Energy Inc. by its majority shareholder.

  • June 16, 2025

    Monsanto Ends Roundup Cancer Case With Midtrial Settlement

    Monsanto confirmed Monday that it has settled a Texas man's Roundup cancer lawsuit shortly before closing arguments in the trial were set to begin.

  • June 16, 2025

    Fed. Circ. Reverses False Ad Verdict Against ThermoLife

    The Federal Circuit on Monday reversed a Florida federal court's decision that ThermoLife falsely promoted amino acid products used in supplements and engaged in unfair competition, but backed a sanctions award over a licensing agreement issue.

  • June 16, 2025

    Ohio Tells 6th Circ. PBM Case Doesn't Target Federal Work

    Ohio urged the Sixth Circuit to send its case accusing Express Scripts and Prime Therapeutics of driving up prescription drug prices through rebate schemes back to state court, arguing the case doesn't target any federal government work by the pharmacy benefit managers.

  • June 16, 2025

    Hemp Farm Says $3.9M Seizure Suit Wasn't Filed Too Late

    A California hemp farm is urging a Tennessee federal court not to throw out its suit as untimely against a Tennessee sheriff's office over $3.9 million in hemp flower the farm claimed was wrongly seized and then destroyed, saying it only learned that the hemp was illegally seized at a hearing for the hemp deliveryman months afterward.

  • June 16, 2025

    Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal

    Supernus Pharmaceuticals, represented by Saul Ewing LLP, said Monday it will acquire Kirkland-advised Sage Therapeutics in a transaction worth as much as $795 million, strengthening Supernus' position in treating neuropsychiatric conditions and expanding its central nervous system health portfolio.

  • June 16, 2025

    King & Spalding Adds HHS Inspector General's Chief Counsel

    An attorney who has spent his entire career with Office of Inspector General for the U.S. Department of Health and Human Services, serving most recently as its chief counsel, has joined King & Spalding LLP's healthcare team in Washington, D.C., the firm announced on Monday.

  • June 16, 2025

    Mass. Judge Blocks NIH Grant Cuts, Points To 'Discrimination'

    A Massachusetts federal judge on Monday blocked the National Institutes of Health from cutting hundreds of grant programs to universities, hospitals and other organizations, saying that in his 40 years on the bench he had never seen such "palpable" racial and LGBTQ discrimination from the government.

  • June 16, 2025

    All 50 States Agree To Purdue Pharma's $7.4B Settlement

    Attorneys general from 55 U.S. states and territories on Monday backed Purdue Pharma's $7.4 billion deal to settle opioid injury claims against the company and the Sackler family, almost a year after the U.S. Supreme Court threw out Purdue's previous plan to end litigation over its role in the opioid epidemic.

  • June 16, 2025

    Justices Turn Away Merck's Bone Drug Warning Label Row

    The U.S. Supreme Court on Monday rejected Merck Sharp & Dohme Corp.'s request to review a Third Circuit decision that more than 1,000 failure-to-warn claims over its osteoporosis drug Fosamax can continue despite the company's assertion that the litigation is barred by federal law.

  • June 13, 2025

    AbbVie Sues Colo. Over State Discount Drug Law

    AbbVie Inc. on Thursday filed suit in Colorado federal court seeking to block an incoming state law it alleges conflicts with the federal 340B drug discount program by forcing pharmaceutical manufacturers to sell drugs at steep discounts to commercial pharmacy chains like Walgreens and CVS.

  • June 13, 2025

    Stewart Releases Flood Of Discretionary Denial Decisions

    The acting U.S. Patent and Trademark Office director issued more than a dozen discretionary denial decisions on Thursday and Friday, where she ruled largely in favor of the challenger, made clear that challenges to young patents have a huge advantage and brought in a denial based on assignor estoppel.

  • June 13, 2025

    Wash. Judge Tosses IUD Suit Against Bayer For Good

    Bayer has beat a negligence lawsuit filed by a woman who claims its Mirena IUD perforated her uterus and migrated after the patient failed to oppose the company's motion to dismiss, a Washington federal judge ruled.

  • June 13, 2025

    More IPO Prospects Ready To Test Market After Chime's Debut

    A venture-backed cancer diagnostics firm and a home insurer are preparing two initial public offerings that could raise $720 million combined next week, joining an energized IPO market following fintech startup Chime Financial Inc.'s debut.

  • June 13, 2025

    23andMe Founder's $305M Bid Buys Back Co. In Ch. 11 Sale

    With a winning bid of $305 million, a nonprofit controlled by 23andMe founder Anne Wojcicki beat out Regeneron Pharmaceuticals to purchase the bankrupt company's assets, 23andMe announced Friday.

Expert Analysis

  • Keys To Handling Digital Investigations In Pharma IP Litigation

    Author Photo

    In the high-stakes realm of pharmaceutical intellectual property litigation, efficient e-discovery and digital investigation workflows are essential to supporting strategic arguments, building defensible cases and proving that the requirements for market entry have been adequately met, says Jerry Lay at FTI Consulting.

  • Series

    Power To The Paralegals: The Value Of Unified State Licensing

    Author Photo

    Texas' proposal to become the latest state to license paraprofessional providers of limited legal services could help firms expand their reach and improve access to justice, but consumers, attorneys and allied legal professionals would benefit even more if similar programs across the country become more uniform, says Michael Houlberg at the University of Denver.

  • What's Next For Lab Test Regulation Without FDA Authority

    Author Photo

    A recent Texas federal court decision vacating the U.S. Food and Drug Administration's final rule that would apply FDA regulations to laboratory-developed tests signals potential positive impacts in the diagnostic space, and could inspire more healthcare entities to litigate against the government, say attorneys at Hooper Lundy.

  • 10 Soft Skills Every GC Should Master

    Author Photo

    As businesses face shifting regulatory and technological uncertainty, general counsel will need to strengthen certain soft skills to succeed, from admitting when they make a mistake to maintaining a healthy dose of dispassion, says Douglas Brown at Manatt.

  • 6 Criteria Can Help Assess Executive Branch Actions

    Author Photo

    With new executive policy changes announced seemingly every day, several questions can help courts, policymakers and businesses determine whether such actions are proper, effective and in keeping with our democratic norms, say Marc Levin and Khalil Cumberbatch at the Council on Criminal Justice.

  • An Unrestrained, Bright-Eyed View Of Legal AI's Future

    Author Photo

    Todd Itami at Covington offers a bright-eyed, laughing-all-the-way, skydive look at what the legal industry could look like after an artificial intelligence revolution, which he believes may happen much sooner and more dramatically than we expect.

  • Tracking The Evolution In Litigation Finance

    Author Photo

    Despite continued innovation, litigation finance remains an immature market with borrowers recieving significantly different terms as lenders learn to value cases, which firms need a strong handle on to ensure lending terms do not overwhelm collateral value, says Robert Wilkins at Lightfoot Franklin.

  • Keys To Regulatory Diligence In Life Sciences Transactions

    Author Photo

    Conducting effective regulatory due diligence for life sciences deals requires careful review of a target company's activities, and separate sets of considerations for commercial and pipeline products, says Anna Zhao at GunnerCooke.

  • How Courts Weigh Section 1782 Discovery For UPC Cases

    Author Photo

    A look at cases from six different federal district courts reveals a number of discretionary factors that influence how courts consider Section 1782 discovery applications in connection with Unified Patent Court proceedings, say attorneys at Finnegan.

  • Opinion

    In Vape Case, Justices Must Focus On Agencies' Results

    Author Photo

    With the U.S. Supreme Court's ruling in U.S. Food and Drug Administration v. Wages and White Lion Investments having put off the question of whether agency decisions arrived at erroneously are always invalid, the court should give the results of agency actions more weight than the reasoning behind them when it revisits this case, says Jonathan Sheffield at Loyola University Chicago School of Law.

  • Series

    Volunteer Firefighting Makes Me A Better Lawyer

    Author Photo

    While practicing corporate law and firefighting may appear incongruous, the latter benefits my legal career by reminding me of the importance of humility, perspective and education, says Nicholas Passaro at Ford.

  • E-Discovery Quarterly: The Perils Of Digital Data Protocols

    Author Photo

    Though stipulated protocols governing the treatment of electronically stored information in litigation are meant to streamline discovery, recent disputes demonstrate that certain missteps in the process can lead to significant inefficiencies, say attorneys at Sidley.

  • Defense Strategies After Justices' Personal Injury RICO Ruling

    Author Photo

    In Medical Marijuana v. Horn, the U.S. Supreme Court recently held that the Racketeer Influenced and Corrupt Organizations Act can be invoked by some plaintiffs with claims arising from personal injuries — but defense counsel can use the limitations on civil RICO claims to seek early dismissal in such cases, say attorneys at Debevoise.

  • Series

    Law School's Missed Lessons: Preparing For Corporate Work

    Author Photo

    Law school often doesn't cover the business strategy, financial fluency and negotiation skills needed for a successful corporate or transactional law practice, but there are practical ways to gain relevant experience and achieve the mindset shifts critical to a thriving career in this space, says Dakota Forsyth at Olshan Frome.

  • 3 Red Flags To Watch For When Valuing Patent Portfolios

    Author Photo

    As forward-looking intellectual property valuations become increasingly popular, recognizing potential concerns during the due diligence process can help develop a more accurate understanding of a portfolio's true value and potential risk, says Keegan Caldwell at Caldwell Law.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.